A Study With GLPG1972 in Osteoarthritis Subjects

Osteoarthritis Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03311009
• Other study ID #: GLPG1972-CL-104
• Status: Completed
• Phase: Phase 1
• First received: October 11, 2017
• Last updated: November 21, 2017
• Start date: May 15, 2017
• Est. completion date: October 25, 2017

Study information

• Verified date: November 2017
• Source: Galapagos NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 25, 2017
• Est. primary completion date: October 25, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects of non-childbearing potential, 50-75 years of age on the date of signing the Informed Consent Form (ICF), inclusive extremes.

2. Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence.

3. A body mass index (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes.

4. Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead ECG, and fasting clinical laboratory profile.

5. Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment.

Exclusion Criteria:

1. Administration of intraarticular glucocorticoid injections or hyaluronan injections in the last 3 months prior to study screening.

2. Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50).

3. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.

4. Positive serology for HBsAg or HCV antibody or history of hepatitis from any cause with the exception of hepatitis A.

5. History of or a current immunosuppressive condition.

6. Clinically significant serious, per investigator's discretion, and/or unstable illness in the 3 months before screening

7. Renal function with an estimated creatinine clearance < 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2).

8. Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration

9. Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration.

10. History of solid organ or hematopoietic cell transplantation.

11. History of malignancy within the past 5 years.

12. Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g., QTcF = 450 ms for males and QTcF = 470 ms for females, or a known long QT syndrome).

13. Significant blood loss (including blood donation [> 450 mL]), or transfusion of any blood product within 12 weeks prior to screening

Related Conditions & MeSH terms

• Osteoarthritis

Intervention

Drug:
• GLPG1972 cohort 1
GLPG1972 dose 1 provided as oral tablets q.d.
• GLPG1972 cohort 2
GLPG1972 dose 2 provided as oral tablets q.d.
• GLPG1972 cohort 3
GLPG1972 dose 3 provided as oral tablets q.d.
• Placebo
Matching placebo provided as oral tablets q.d.

Locations

Country	Name	City	State
United States	Covance Daytona Beach	Daytona Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Galapagos NV

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events	To assess safety and tolerability of GLPG1972 in OA patients	From screening until the final follow up visit (day 50)
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs	To assess safety and tolerability of GLPG1972 in OA patients	From screening until the final follow up visit (day 50)
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations	To assess safety and tolerability of GLPG1972 in OA patients	Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination	To assess safety and tolerability of GLPG1972 in OA patients	Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG	To assess safety and tolerability of GLPG1972 in OA patients	Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)
Primary	Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment	To assess safety and tolerability of GLPG1972 in OA patients	Day -1 to days 1 and Day 10 to day 11
Primary	The maximum observed plasma concentration of GLPG1972 (Cmax)	To assess PK of GLPG1972 in OA patients	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Primary	The time (tmax) to reach Cmax of GLPG1972	To assess PK of GLPG1972 in OA patients	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Primary	The plasma concentration of GLPG1972 24 after the last dose	To assess PK of GLPG1972 in OA patients	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Primary	The area under the plasma concentration time curve from time 0 until the last quantifieble dose	To assess PK of GLPG1972 in OA patients	Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Secondary	Percentage reduction of neo-epitope ARGS vs baseline	To assess PD of GLPE1972 in OA patients	Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)